Summary

Extracorporeal membrane oxygenation (ECMO) is a type of life support used when a person's heart and lungs are not working properly. ECMO takes blood out of body, sends it through devices to add oxygen and remove carbondioxide, and then pumps the blood back into body. This process provides temporary support, allowing the heart and lungs to rest and recover. ECMO is commonly used in critical care settings for conditions such as severe pneumonia, acute respiratory distress syndrome (ARDS), and cardiac arrest. It is typically categorized into two types, such as veno-arterial (VA) ECMO, which supports both heart and lung function, and veno-venous (VV) ECMO, which primarily supports lung function. While ECMO can be lifesaving, it is a complex procedure that requires continuous monitoring and is associated with potential risks, including bleeding, infection, and complications related to blood clotting.
The extracorporeal membrane oxygenation (ECMO) market is driven by rise in prevalence of respiratory and cardiac failures, fueled by conditions such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. The increase in prevalence of respiratory diseases, particularly among aging population and critically ill patients, is boosting demand for ECMO systems as a life-saving intervention. In addition, rise in government initiatives and funding aimed at improving critical care infrastructure is also driving the market growth. Many countries are expanding ECMO programs in hospitals, increasing access to extracorporeal life support. Furthermore, rise in awareness among healthcare professionals about the advantages of ECMO in managing severe respiratory and cardiac conditions is leading to a greater adoption of the ECMO solutions. As more healthcare providers recognize its potential in saving lives and improving patient outcomes, the demand for ECMO systems continues to rise, thereby contributing to the growth of the market.
However, high costs associated with ECMO systems, including equipment, maintenance, and operational expenses, make it less accessible, particularly in developing regions, thereby restricting the market growth. The procedure requires highly trained healthcare professionals, and a shortage of skilled personnel limits its widespread adoption. On the other hand, innovations in portable and user-friendly ECMO systems are enhancing accessibility and efficiency, making them more viable for use in emergency and transport settings which provides an opportunity for the market growth.
The extracorporeal membrane oxygenation market is segmented into component, modulation, application, patient type, and region. By component, the market is segregated into controllers, pumps, oxygenator, cannula, and accessories. By modulation, the market is categorized into veno arterial (VA), veno venous (VV), and others. By application, the market is classified into cardiac diseases, respiratory disorders, and extracorporeal cardiopulmonary resuscitation. By patient type, the market is classified into neonates, pediatric, and adult. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, UAE, Argentina, and Rest of LAMEA).
Major players that operate in the extracorporeal membrane oxygenation market are Medtronic plc, Terumo Corporation, Fresenius SE & Co. KGaA, Getinge, Microport Scientific Corporation, LivaNova, Inc., EUROSETS, CytoSorbents Corporation, Abbott Laboratories, and Chalice Medical Ltd. Key players have adopted product launch, agreement, collaboration, expansion, and product approval as key developmental strategies to improve the product portfolio of the extracorporeal membrane oxygenation market.
Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the extracorporeal membrane oxygenation market analysis from 2023 to 2035 to identify the prevailing extracorporeal membrane oxygenation market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the extracorporeal membrane oxygenation market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global extracorporeal membrane oxygenation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Patient/epidemiology data at country, region, global level
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● SWOT Analysis
Key Market Segments
By Modulation
● Others
● Veno arterial
● Veno venous
By Application
● Cardiac Diseases
● Respiratory Disorders
● Extracorporeal Cardiopulmonary Resuscitation
By Patient Type
● Neonates
● Pediatric
● Adult
By Component
● Controllers
● Pumps
● Oxygenator
● Cannula
● Accessories
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Russia
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Thailand
○ Malaysia
○ Indonesia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ UAE
○ Argentina
○ Rest of LAMEA
● Key Market Players
○ Medtronic plc
○ Terumo Corporation
○ Eurosets
○ Getinge
○ Chalice Medical Ltd.
○ MicroPort Scientific Corporation
○ LivaNova PLC
○ CytoSorbents Corporation
○ Fresenius SE & Co. KGaA
○ Abbott Laboratories

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growing prevalence of respiratory and cardiac diseases
3.4.1.2. Government initiatives and healthcare funding
3.4.1.3. Increasing adoption of ECMO in pediatric and neonatal care
3.4.2. Restraints
3.4.2.1. High cost of ECMO systems and procedures
3.4.3. Opportunities
3.4.3.1. High growth potential in emerging countries
3.4.3.2. Technological advancements in ECMO systems
CHAPTER 4: EXTRACORPOREAL MEMBRANE OXYGENATION MARKET, BY COMPONENT
4.1. Overview
4.1.1. Market size and forecast
4.2. Controllers
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Pumps
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Oxygenator
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Cannula
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Accessories
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: EXTRACORPOREAL MEMBRANE OXYGENATION MARKET, BY MODULATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Veno arterial
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Veno venous
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: EXTRACORPOREAL MEMBRANE OXYGENATION MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cardiac Diseases
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Respiratory Disorders
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Extracorporeal Cardiopulmonary Resuscitation
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: EXTRACORPOREAL MEMBRANE OXYGENATION MARKET, BY PATIENT TYPE
7.1. Overview
7.1.1. Market size and forecast
7.2. Neonates
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Pediatric
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Adult
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: EXTRACORPOREAL MEMBRANE OXYGENATION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Component
8.2.3. Market size and forecast, by Modulation
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by Patient Type
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Component
8.2.6.1.2. Market size and forecast, by Modulation
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Patient Type
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Component
8.2.6.2.2. Market size and forecast, by Modulation
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Patient Type
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Component
8.2.6.3.2. Market size and forecast, by Modulation
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by Patient Type
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Component
8.3.3. Market size and forecast, by Modulation
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by Patient Type
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Component
8.3.6.1.2. Market size and forecast, by Modulation
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Patient Type
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Component
8.3.6.2.2. Market size and forecast, by Modulation
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Patient Type
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Component
8.3.6.3.2. Market size and forecast, by Modulation
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Patient Type
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Component
8.3.6.4.2. Market size and forecast, by Modulation
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Patient Type
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Component
8.3.6.5.2. Market size and forecast, by Modulation
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Patient Type
8.3.6.6. Russia
8.3.6.6.1. Market size and forecast, by Component
8.3.6.6.2. Market size and forecast, by Modulation
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Patient Type
8.3.6.7. Rest of Europe
8.3.6.7.1. Market size and forecast, by Component
8.3.6.7.2. Market size and forecast, by Modulation
8.3.6.7.3. Market size and forecast, by Application
8.3.6.7.4. Market size and forecast, by Patient Type
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Component
8.4.3. Market size and forecast, by Modulation
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by Patient Type
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Component
8.4.6.1.2. Market size and forecast, by Modulation
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Patient Type
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Component
8.4.6.2.2. Market size and forecast, by Modulation
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Patient Type
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Component
8.4.6.3.2. Market size and forecast, by Modulation
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Patient Type
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Component
8.4.6.4.2. Market size and forecast, by Modulation
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Patient Type
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Component
8.4.6.5.2. Market size and forecast, by Modulation
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Patient Type
8.4.6.6. Thailand
8.4.6.6.1. Market size and forecast, by Component
8.4.6.6.2. Market size and forecast, by Modulation
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Patient Type
8.4.6.7. Malaysia
8.4.6.7.1. Market size and forecast, by Component
8.4.6.7.2. Market size and forecast, by Modulation
8.4.6.7.3. Market size and forecast, by Application
8.4.6.7.4. Market size and forecast, by Patient Type
8.4.6.8. Indonesia
8.4.6.8.1. Market size and forecast, by Component
8.4.6.8.2. Market size and forecast, by Modulation
8.4.6.8.3. Market size and forecast, by Application
8.4.6.8.4. Market size and forecast, by Patient Type
8.4.6.9. Rest of Asia-Pacific
8.4.6.9.1. Market size and forecast, by Component
8.4.6.9.2. Market size and forecast, by Modulation
8.4.6.9.3. Market size and forecast, by Application
8.4.6.9.4. Market size and forecast, by Patient Type
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Component
8.5.3. Market size and forecast, by Modulation
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by Patient Type
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Component
8.5.6.1.2. Market size and forecast, by Modulation
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Patient Type
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Component
8.5.6.2.2. Market size and forecast, by Modulation
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Patient Type
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Component
8.5.6.3.2. Market size and forecast, by Modulation
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by Patient Type
8.5.6.4. UAE
8.5.6.4.1. Market size and forecast, by Component
8.5.6.4.2. Market size and forecast, by Modulation
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by Patient Type
8.5.6.5. Argentina
8.5.6.5.1. Market size and forecast, by Component
8.5.6.5.2. Market size and forecast, by Modulation
8.5.6.5.3. Market size and forecast, by Application
8.5.6.5.4. Market size and forecast, by Patient Type
8.5.6.6. Rest of LAMEA
8.5.6.6.1. Market size and forecast, by Component
8.5.6.6.2. Market size and forecast, by Modulation
8.5.6.6.3. Market size and forecast, by Application
8.5.6.6.4. Market size and forecast, by Patient Type
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Getinge
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Medtronic plc
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Terumo Corporation
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. MicroPort Scientific Corporation
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. LivaNova PLC
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Eurosets
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.7. CytoSorbents Corporation
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Key strategic moves and developments
10.8. Abbott Laboratories
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Fresenius SE & Co. KGaA
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Chalice Medical Ltd.
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio